Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;8(1):97-105.
doi: 10.15171/apb.2018.012. Epub 2018 Mar 18.

The Eeffect of Metformin Combined with Calcium-Vitamin D3 Against Diet-Induced Nonalcoholic Fatty Liver Disease

Sara Shojaei Zarghani  1 , Samin Abbaszadeh  2 , Mohammad Alizadeh  3 , Maryam Rameshrad  4 , Alireza Garjani  4 , Hamid Soraya  2
Affiliations

The Eeffect of Metformin Combined with Calcium-Vitamin D3 Against Diet-Induced Nonalcoholic Fatty Liver Disease

Sara Shojaei Zarghani et al. Adv Pharm Bull. 2018 Mar.

Erratum in

  • Erratum: Correction of Title.
    Shojaei Zarghani S, Abbaszadeh S, Alizadeh M, Rameshrad M, Garjani A, Soraya H. Shojaei Zarghani S, et al. Adv Pharm Bull. 2021 Jan;11(1):205. doi: 10.34172/apb.2021.089. Epub 2020 Nov 7. Adv Pharm Bull. 2021. PMID: 33747869 Free PMC article.

Abstract

Purpose: Metformin is one of the most popular drugs tested against nonalcoholic fatty liver disease (NAFLD). The present study aimed to investigate whether calcium-vitamin D3 cosupplementation will intensify the effect of metformin on the prevention of high-fat, high-fructose (HFFr) diet-induced hepatic steatosis. Methods: Male wistar rats (210±16 g) were assigned into the following seven groups: a Control group to receive a standard chow and six HFFr-fed groups to receive diets containing either normal (0.5% calcium and 1000 IU/kg vitamin D3) or high amount of calcium and vitamin D3 (2.4% calcium and 10000 IU/kg vitamin D3) (CaD), in combination with gastric gavage administration of either saline or 25 or 200 mg/kg body weight/day metformin. After 60 days, rats were assessed with respect to their anthropometric, metabolic and hepatic parameters, as well as their hepatic AMP-activated protein kinase (AMPK) phosphorylation. Results: Metformin and CaD, either alone or in combination, caused a significant reduction in HFFr diet-induced high serum aspartate aminotransferase (AST), hepatic steatosis and lipid accumulation without effect on insulin resistance and AMPK phosphorylation. In addition, slightly (and non-significantly) better effects of the combination in ameliorating steatosis and hepatic cholesterol content were observed. Conclusion: Taken together, our results suggest that metformin and CaD could protect against the onset of HFFr diet-induced NAFLD in an insulin and AMPK-independent manner, without any marked additional benefits of their combination.

Keywords: AMP-activated protein kinase; Calcium; Metformin; Nonalcoholic fatty liver disease; Vitamin D3.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
See this image and copyright information in PMC

References

    1. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Cl Lab Sci. 2011;48(3):97–113. doi: 10.3109/10408363.2011.596521. - DOI - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Am J Gastroenterol. 2012;107(6):811–26. doi: 10.1038/ajg.2012.128. - DOI - PubMed
    1. Wainwright P, Byrne CD. Bidirectional relationships and disconnects between nafld and features of the metabolic syndrome. Int J Mol Sci. 2016;17(3):367. doi: 10.3390/ijms17030367. - DOI - PMC - PubMed
    1. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–44. doi: 10.1111/jgh.13264. - DOI - PubMed
    1. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221–39. doi: 10.2147/CEG.S62831. - DOI - PMC - PubMed

LinkOut - more resources